Literature DB >> 30340901

Design, synthesis, cholinesterase inhibition and molecular modelling study of novel tacrine hybrids with carbohydrate derivatives.

João Paulo Bizarro Lopes1, Luana Silva1, Gabriela da Costa Franarin1, Marco Antonio Ceschi2, Diogo Seibert Lüdtke1, Rafael Ferreira Dantas3, Cristiane Martins Cardoso de Salles4, Floriano Paes Silva-Jr3, Mario Roberto Senger5, Isabella Alvim Guedes6, Laurent Emmanuel Dardenne7.   

Abstract

A series of hybrids containing tacrine linked to carbohydrate-based moieties, such as d-xylose, d-ribose, and d-galactose derivatives, were synthesized by the nucleophilic substitution between 9-aminoalkylamino-1,2,3,4-tetrahydroacridines and the corresponding sugar-based tosylates. All compounds were found to be potent inhibitors of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in the nanomolar IC50 scale. Most of the d-xylose derivatives (6a-e) were selective for AChE and the compound 6e (IC50 = 2.2 nM for AChE and 4.93 nM for BuChE) was the most active compound for both enzymes. The d-galactose derivative 8a was the most selective for AChE exhibiting an IC50 ratio of 7.6 for AChE over BuChE. Only two compounds showed a preference for BuChE, namely 7a (d-ribose derivative) and 6b (d-xylose derivative). Molecular docking studies indicated that the inhibitors are capable of interacting with the entire binding cavity and the main contribution of the linker is to enable the most favorable positioning of the two moieties with CAS, PAS, and hydrophobic pocket to provide optimal interactions with the binding cavity. This finding is reinforced by the fact that there is no linear correlation between the linker size and the observed binding affinities. The majority of the new hybrids synthesized in this work do not violate the Lipinski's rule-of-five according to FAF-Drugs4, and do not demonstrated predicted hepatotoxicity according ProTox-II.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer; Carbohydrate; Cholinesterases; Galactose; Molecular modeling; Ribose; Tacrine; Xylose

Mesh:

Substances:

Year:  2018        PMID: 30340901     DOI: 10.1016/j.bmc.2018.10.003

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

Review 1.  An overview on the synthesis of carbohydrate-based molecules with biological activity related to neurodegenerative diseases.

Authors:  João Paulo B Lopes; Luana Silva; Diogo S Lüdtke
Journal:  RSC Med Chem       Date:  2021-09-08

Review 2.  Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer's Disease and Future Perspectives.

Authors:  Natália Chermont Dos Santos Moreira; Jéssica Ellen Barbosa de Freitas Lima; Marcelo Fiori Marchiori; Ivone Carvalho; Elza Tiemi Sakamoto-Hojo
Journal:  J Alzheimers Dis Rep       Date:  2022-04-18

Review 3.  Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer's Disease Therapy.

Authors:  Agnieszka Zagórska; Anna Jaromin
Journal:  Molecules       Date:  2020-07-23       Impact factor: 4.411

4.  Late-Stage Modification of Medicine: Pd-Catalyzed Direct Synthesis and Biological Evaluation of N-Aryltacrine Derivatives.

Authors:  Lin-Xi Wan; Yong-Qi Zhen; Zhen-Xiang He; Yang Zhang; Lan Zhang; Xiaohuan Li; Feng Gao; Xian-Li Zhou
Journal:  ACS Omega       Date:  2021-04-02

Review 5.  Pharmacotherapy of Alzheimer's Disease: Seeking Clarity in a Time of Uncertainty.

Authors:  Nurul Husna Ibrahim; Mohamad Fairuz Yahaya; Wael Mohamed; Seong Lin Teoh; Chua Kien Hui; Jaya Kumar
Journal:  Front Pharmacol       Date:  2020-03-24       Impact factor: 5.810

6.  Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors.

Authors:  Maja Przybyłowska; Krystyna Dzierzbicka; Szymon Kowalski; Klaudia Chmielewska; Iwona Inkielewicz-Stepniak
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.